Tin tức & Cập nhật
Lọc theo Chuyên ngành:
![Venetoclax + chemo disappoints in double-hit lymphoma trial](https://sitmspst.blob.core.windows.net/images/articles/ash213-da-epoch-rvenetoclax-lymphoma-244b7245-119c-4952-adc4-39552f265164-square.jpg)
Venetoclax + chemo disappoints in double-hit lymphoma trial
In patients with double-hit lymphoma (DHL), the addition of the BCL2 inhibitor venetoclax to a chemoimmunotherapeutic regimen comprising DA-EPOCH-R* led to excess treatment-related mortality compared with DA-EPOCH-R alone, according to the initial results of the phase II/III Alliance A051701 trial.
Venetoclax + chemo disappoints in double-hit lymphoma trial
27 Dec 2021![Lumateperone improves depression symptoms in bipolar disorder](https://sitmspst.blob.core.windows.net/images/articles/bipolar-disordermania-3076c890-78e6-4c3e-ba9d-18f3e9bfaa7a-square.jpg)
Lumateperone improves depression symptoms in bipolar disorder
Treatment with 42-mg lumateperone daily leads to significant improvement in depression symptoms, with no serious safety issues, among patients with major depressive episodes associated with both bipolar I and II disorders, a study has shown.
Lumateperone improves depression symptoms in bipolar disorder
26 Dec 2021![Ticagrelor monotherapy following short-term DAPT more suitable for seniors with ACS](https://sitmspst.blob.core.windows.net/images/articles/reduced-cv-risk-no-increased-bleeding-with-extended-term-dapt-post-pci-8787d049-4ad6-422d-9ad4-e39f68e40efa-square.jpg)
Ticagrelor monotherapy following short-term DAPT more suitable for seniors with ACS
For older acute coronary syndrome (ACS) patients with implanted bioabsorbable polymer sirolimus-eluting stents, a strategy involving ticagrelor monotherapy after 3‐month dual antiplatelet therapy (DAPT) is better than ticagrelor‐based 12‐month DAPT, according to a post hoc analysis of the TICO* trial. Furthermore, the beneficial effect of ticagrelor monotherapy increases with age and is strongest among patients aged ≥64 years.
Ticagrelor monotherapy following short-term DAPT more suitable for seniors with ACS
25 Dec 2021![Sintilimab-IBI305-chemo improves PFS in EGFRm non-squamous NSCLC](https://sitmspst.blob.core.windows.net/images/articles/sintilimab-ibi305-chemo-improves-pfs-in-egfrm-non-squamous-nsclc-2a23b1b9-601f-4573-8406-9a8c832c702e-square.jpg)
Sintilimab-IBI305-chemo improves PFS in EGFRm non-squamous NSCLC
The combination of the anti-PD-1 monoclonal antibody sintilimab with the bevacizumab biosimilar IBI305 and pemetrexed and cisplatin chemotherapy improved progression-free survival (PFS) in patients with EGFR*-mutated (EGFRm) non-squamous non-small-cell lung cancer (NSCLC), according to interim analysis results of the phase III ORIENT-31 trial from China.